Optimizing Drug Safety with AI
AI Identifies IRS4 as New Target for Solid Tumors
St. Jude researchers use AI and genetic data to pinpoint a cancer dependency with low risk of side effects.
A digital visualization of genetic data and molecular structures being analyzed by an artificial intelligence interface for cancer research.
Photo: Avantgarde News
Investigators at St. Jude Children's Research Hospital identified IRS4 as a potential dependency in several solid tumor types [1]. The team used an AI-assisted approach to analyze genetic data and prioritize specific targets [1]. This method identifies weaknesses in cancer cells while minimizing risks to healthy tissues [1].
The model specifically prioritized targets with a limited risk of side effects [1]. By evaluating potential drug toxicity early in the search, researchers aim to streamline the development of new treatments [1]. This study provides a proof of principle for using machine learning to find safer therapeutic options [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The risk level is elevated to high because the report relies on a single source domain (stjude.org), which does not meet the recommendation of three independent domains.
Sources
Related stories
View all
Topics
About the author
Avantgarde News Desk covers optimizing drug safety with ai and editorial analysis for Avantgarde News.